Medicare coverage of ClonoSEQ shows market progress for next-gen sequencing

Those cells that survive the initial cancer treatment are often the ones that cause a patient to relapse; the test will benefit patients by providing them with better personalised treatment during their care. Credit: Christaras A



  • Next-generation diagnostics